two new opioid formulations, Oxecta and Lazanda

October 2011

You'll hear about two new opioid formulations, Oxecta and Lazanda.

Oxecta (OX-ec-tah) is a new tamper-resistant, immediate-release oxycodone tab. It's formulated to discourage potential abusers from crushing, chewing, snorting, or injecting the opioid.

The tab breaks into chunks instead of a powder if crushed...and turns into a gel if mixed with liquid. It also contains sodium laurel sulfate, which irritates the nose if it's snorted.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Anticoagulants controversy over which ORAL anticoagulant to use to prevent strokes in patients with atrial fibrillation
Antidepressants citalopram doses should not exceed 40 mg/day for anyone...or 20 mg/day for most patients over age 60
Antidepressants Reps are filling up sample closets, hoping prescribers will use Deplin to improve the efficacy of antidepressants
Respiratory & Allergy chronic azithromycin to PREVENT recurrent COPD exacerbations
Influenza the same flu strains as last year, the first INTRADERMAL flu vaccine, and a new Tamiflu suspension
Opioids two new opioid formulations, Oxecta and Lazanda
Women's Health tighter and more aggressive control of hypothyroidism before and during pregnancy
Antipsychotics serious allergic reactions to the antipsychotic, Saphris (asenapine)
Cardiology MORE safety concerns with dronedarone (Multaq)
Geriatrics manage elderly dementia patients who have behavior issues
Corticosteroids whether hyperglycemia can occur with non-oral corticosteroids
Interactions Computer alerts about an interaction between oral potassium chloride (Micro-K, etc) and anticholinergics are causing confusion

two new opioid formulations, Oxecta and Lazanda

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents